Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients

American Journal of Cardiology

Volumn 104, Issue 8, 2009, Pages 1078-1082

  Cuisset, Thomas ^a   Frere, Corinne ^a   Quilici, Jacques ^a   Gaborit, Bénédicte ^a   Castelli, Christel ^b   Poyet, Raphael ^a   Bali, Laurent ^a   Morange, Pierre Emmanuel ^a   Alessi, Marie Christine ^a   Bonnet, Jean Louis ^a  

^a TIMONE HOSPITAL   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY STENT; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS PREVENTION;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PROTEINS; CELL ADHESION MOLECULES; CORONARY THROMBOSIS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; ODDS RATIO; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; RISK FACTORS; ROC CURVE; STENTS; TICLOPIDINE;

EID: 70349510067     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.06.007     Document Type: Article

References (22)

1. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., and Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
2. Silber S., Albertsson P., Avilés F.F., Camici P.G., Colombo A., Hamm C., Jørgensen E., Marco J., Nordrehaug J.E., Ruzyllo W., Urban P., Stone G.W., Wijns W., and Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary intervention. Eur Heart J 26 (2005) 804-847
3. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., and Costa M.A. Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
4. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
5. Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., Bonnet J.L., and Alessi M.C. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
6. Geisler T., Langer H., Wydymus M., Göhring K., Zürn C., Bigalke B., Stellos K., May A.E., and Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
7. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., Gick M., Caputo A., Büttner H.J., and Neumann F.J. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
8. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., and Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
9. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., Barragan P., and Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis before percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5 (2007) 1630-1636
10. Frere C., Cuisset T., Quilici J., Camoin L., Carvajal J., Morange P.E., Lambert M., Juhan-Vague I., Bonnet J.L., and Alessi M.C. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 98 (2007) 838-843
11. Schwarz U.R., Geiger J., Walter U., and Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 82 (1999) 1145-1152
12. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W., and Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
13. Serruys P.W., Strauss B.H., Beatt K.J., Bertrand M.E., Puel J., Rickards A.F., Meier B., Goy J.J., Vogt P., and Kappenberger L. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 324 (1991) 13-17
14. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick P., and CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the CLopidogrel ASpirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
15. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., Slama M., Milleron O., Collet J.P., Henry P., Beygui F., Drouet L., and ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
16. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., Lehmann A., Lambert M., Bonnet J.L., and Alessi M.C. Benefit of a 600 mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
17. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., Simeoni M.C., Barragan P., Dignat-George F., and Paganelli F. Adjusted clopidogrel loading doses according to VASP phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
18. Cuisset T., Frere C., Quilici J., Morange P.E., Mouret J.P., Bali L., Moro P.J., Lambert M., Alessi M.C., and Bonnet J.L. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non responders: a prospective, randomized study. J Am Coll Cardiol Interv 1 (2008) 649-653
19. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M., and TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
20. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., and Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
21. Cuisset T., Hamilos M., Sarma J., Sarno G., Wyffels E., Vanderheyden M., Barbato E., Bartunek J., De Bruyne B., and Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 101 (2008) 1700-1703
22. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., Buonamici P., Antoniucci D., Abbate R., and Gensini G. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119 (2009) 237-242